Syncor announces first U.S. I-125 seed user

AuntMinnie.com staff writers

Jul 25, 2000

Radiopharmaceutical provider Syncor has announced that the University of Kentucky Chandler Medical Center in Lexington, KY, has become the first U.S. institution to use the vendor’s PharmaSeed Iodine-125 brachytherapy seeds for the treatment of localized prostate cancer. The first I-125 brachytherapy procedures outside the U.S. were performed in March in Thailand, according to the Woodland Hills, CA-based firm.

By AuntMinnie.com staff writers
July 26, 2000
Related Reading

Syncor brachytherapy seeds cleared by FDA, January 12, 2000.

Copyright © 2000 AuntMinnie.com

Copyright © 2000 AuntMinnie.com

Top 10 Gold Social

Body composition analysis, MRI safety topped 2024's most read articles

December 20, 2024

Neiman index outperforms Charlson for predicting imaging use

December 20, 2024

Mammogram Patient

40% of women in their 40s forgo biennial breast cancer screening

December 20, 2024

Corporate Transparency

Practices must comply with the Corporate Transparency Act

December 20, 2024

Body composition analysis, MRI safety topped 2024's most read articles

While COVID and radiology salaries hit the top of AuntMinnie.com's Top 10 most-read posts of 2023, they rounded out the bottom of this year's list.

December 20, 2024

Top 10 Gold Social

Neiman index outperforms Charlson for predicting imaging use

By Kate Madden Yee

The Neiman Imaging Comorbidity Index outperforms the Charlson Comorbidity Index for predicting advanced imaging use.

December 20, 2024

40% of women in their 40s forgo biennial breast cancer screening

By Amerigo Allegretto

About two in every five women in their 40s do not undergo biennial breast cancer screening per USPSTF recommendations.

December 20, 2024

Mammogram Patient

Practices must comply with the Corporate Transparency Act

By Healthcare Administrative Partners

A new column from Healthcare Administrative Partners discusses the impact of the Corporate Transparency Act on medical practices.

December 20, 2024

Corporate Transparency

Kidneys appear to tolerate Lu-177 treatments

Kidney-absorbed doses of lutetium-177 (Lu-177)-based treatments for prostate cancer and neuroendocrine tumors appear to be below toxicity thresholds.

December 19, 2024

Higher Medicaid-to-Medicare reimbursement ratios boost imaging use

By Kate Madden Yee

Higher Medicaid-to-Medicare reimbursement ratios are linked to increased likelihood of Medicaid patients receiving CT, MR, ultrasound, and x-ray imaging.

December 19, 2024

Money Hundred Bills

AI algorithm 'harmonizes' brain MRI data from different scanners

By Kate Madden Yee

A novel machine-learning algorithm used with MRI can harmonize brain volumetric data of patients undergoing Alzheimer's disease assessment gathered from different scanners.

December 18, 2024

Recommendations address AI bias, data transparency

By Amerigo Allegretto

New recommendations seek to make medical AI safe and effective for everyone by tackling the issues of bias and transparency.

December 18, 2024

Artificial Intelligence Ai Suit

AdvaMed applauds House Task Force on AI report

By AuntMinnie.com staff writers

AdvaMed commended the end-of-year report submitted to the U.S. Congress on December 17 by the House Task Force on AI.

December 18, 2024

Artificial Intelligence Ai Abstract 400

African American men respond more favorably to Ra-223 therapy

African American men with metastatic castrate-resistant prostate cancer may respond more favorably than white men to treatment with radium-223.

December 17, 2024

Prostate Imaging

What radiology trainees should know heading into 2025

Radiologists discuss specialty and job market: 10 takeaways.

December 17, 2024

Radiology Practice Models 2024

Solis acquires San Antonio, TX imaging centers

By AuntMinnie.com staff writers

Solis Mammography has acquired Avestēe Women's Imaging Centers in San Antonio, TX.

December 16, 2024

Breast Screening Mammo

Page 1 of 107